Compare Novo Nordisk A/S (NVO) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs BlackRock TCP Capital Corp — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while BlackRock TCP Capital Corp trades at $4.01 (market cap $337.71M). The key difference: Novo Nordisk A/S is far larger — about 489.5× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (18.88%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and BlackRock TCP Capital Corp for 88 Days on average.
| NVO | TCPC | |
|---|---|---|
Market Cap | $165.31B | $337.71M |
Volume | 11,432,838 | 436,109 |
Sector | Health | Financials |
52-Week High | $63.98 | $6.20 |
52-Week Low | $35.29 | $3.13 |
Typical Hold Time | 116 Days | 88 Days |
Enterprise Value | $179.56B | $1.09B |
Dividend Yield | 4.71% | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
TCPC trades at $4.01, up 1.78% with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.22, beating expectations, and announced a $523 million portfolio sale to reduce leverage. Despite negative revenue and net income trends, the stock trades at a discount to book value with a P/B of 0.61. Analyst consensus shows 30.77% buy ratings with no sell recommendations.
The outlook remains cautious due to declining revenue and negative profitability metrics, though strategic portfolio sales and dividend payments provide some stability. Key risks include ongoing net losses and class action litigation, while institutional sentiment appears mixed with technical indicators suggesting near-term bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
